PLA1A and colorectal carcinoma: CRC cell lines were treated with two commercially available NMD inhibitors: (i) amlexanox, for which the exact mechanism of action is still unknown30, and (ii) NMDI-1, which inhibits the dephosphorylation of UPF1 and thereby keeps it in a non-active state31.